We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement
Analytical Cannabis Logo
×
Home > News > Psychedelics > Content Piece

Awakn’s Ketamine-gambling Disorder Study Expands to Test Whether the Drug Can Also Treat Binge Eating

By Leo Bear-McGuinness

Published: Jan 06, 2022   

Complete the form below and we will email you a PDF version of "Awakn’s Ketamine-gambling Disorder Study Expands to Test Whether the Drug Can Also Treat Binge Eating"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Analytical Cannabis?

Analytical Cannabis Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Image credit: Szabo Viktor via Unsplash

Back in August of 2021, recruitment was underway for a first-of-its-kind study to assess whether ketamine can help treat gambling addiction.

Now, the company behind the trial has expanded it to include three other behavioral addictions: binge eating disorder, compulsive sexual behavior, and internet gaming disorder.

The expanded trial will also be the first of its kind and will be led by Celia Morgan, a professor of psychopharmacology at the University of Exeter and head of ketamine-assisted therapy for addiction at Awakn, the biotechnology company behind the study.


Ketamine for breakfast

According to some estimates, binge eating disorder affects around 110 million people around the world; internet gaming disorder is thought to affect 238 million and sexual compulsive behavior is thought to affect up to 350 million. Gambling disorder is understood to be one of the most prevalent addiction disorders, affecting an estimated 450 million people around the world.

“We are delighted to expand this research and to make further inroads into a treatment area that has had no material pharmacological advancements in far too long, all the while the number of people suffering has steadily increased,” Morgan said in a statement.

“We hope this will give us valuable insights to push our ketamine program forward and help these people as quickly as possible.”

Morgan and her team aim to explore whether ketamine can help break the neural patterns in the brain that facilitate these behaviors. They’ll study whether the drug can increase the neuroplasticity of recruits using an electroencephalogram (EEG).

Speaking to Analytical Cannabis last year on Awakn’s gambling disorder study, Morgan explained the study’s design and her team aimed to test ketamine’s potential as a behavior-disrupting drug.

“We are using one of the capacities of the ketamine which is to block a process of re-stabilization of memory. In the study that we’re doing, we’re going to reactivate gambling memories. We’ll be showing people, depending on what their modality of gambling is, a roulette wheel or slot machines or horses, and this reactivates the memory,” she said.

“Normally in memory, this means that this memory becomes active and you’re able to update it. Then it’s restabilized – saved again, in computer terms – and is laid down more strongly. If you give ketamine during this time of reactivation, what’s been found particularly in animals is that this can weaken the memory trace. That’s what we’re looking at in this study.”

 

Like what you just read? You can find similar content on the topic tags shown below.

Science & Health Psychedelics

Stay connected with the latest news in cannabis extraction, science and testing

Get the latest news with the FREE weekly Analytical Cannabis newsletter

 
Advertisement